Mineralys Therapeutics, Inc.

MLYSNASDAQHealthcare● Active

$23.13

$-0.56(-2.36%)

Market Cap$1.5B

P/E Ratio—

52W High$47.65

52W Low$12.59

Avg Volume1.4M

Open$23.76

Beta0.56

Insider Trades Ownership Employees

Mineralys Therapeutics, Inc. (MLYS) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · MLYS · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.05

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 5%Active transactions only · RSU vesting excluded95% Sell ↓

Mineralys Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

MLYS insider buying and selling by quarter

MLYS insider selling · MLYS insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

4.0M2.0M0

2024 Q3

2024 Q4

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2026 Q1

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · MLYS ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

MLYS executive sell shares · MLYS board member insider trading · MLYS insider trading SEC filing

Showing 62 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
May 18, 2026	Rodman David Malcom Chief Medical Officer	Option	417	$15.44	$6K	63,860	Form 4
May 18, 2026	Rodman David Malcom Chief Medical Officer	Sale	417	$27.55	$11K	63,443	Form 4
May 13, 2026	Rodman David Malcom Chief Medical Officer	Option	4,166	$14.25	$59K	77,499	Form 4
May 12, 2026	Rodman David Malcom Chief Medical Officer	Option	6,348	$1.08	$7K	76,140	Form 4
May 13, 2026	Rodman David Malcom Chief Medical Officer	Option	3,541	$10.20	$36K	73,333	Form 4
May 11, 2026	Rodman David Malcom Chief Medical Officer	Option	2,171	$16.00	$35K	71,963	Form 4
May 12, 2026	Rodman David Malcom Chief Medical Officer	Sale	6,348	$29.36	$186K	69,792	Form 4
May 11, 2026	Rodman David Malcom Chief Medical Officer	Sale	2,171	$29.71	$65K	69,792	Form 4
May 13, 2026	Rodman David Malcom Chief Medical Officer	Sale	14,056	$28.58	$402K	63,443	Form 4
Apr 17, 2026	Rodman David Malcom Chief Medical Officer	Option	416	$15.44	$6K	70,208	Form 4
Apr 17, 2026	Rodman David Malcom Chief Medical Officer	Sale	416	$31.33	$13K	69,792	Form 4
Apr 13, 2026	Rodman David Malcom Chief Medical Officer	Option	4,167	$14.25	$59K	90,198	Form 4
Apr 13, 2026	Rodman David Malcom Chief Medical Officer	Option	3,542	$10.20	$36K	86,031	Form 4
Apr 13, 2026	Rodman David Malcom Chief Medical Officer	Option	6,349	$1.08	$7K	82,489	Form 4
Apr 13, 2026	Rodman David Malcom Chief Medical Officer	Sale	14,058	$26.54	$373K	76,140	Form 4
Apr 15, 2026	Rodman David Malcom Chief Medical Officer	Sale	6,348	$27.66	$176K	69,792	Form 4
Apr 13, 2026	Congleton Jon CEO · Director	Sale	15,730	$26.83	$422K	689,321	Form 4
Apr 9, 2026	Rodman David Malcom Chief Medical Officer	Option	2,170	$16.00	$35K	78,310	Form 4
Apr 9, 2026	Rodman David Malcom Chief Medical Officer	Sale	2,170	$27.38	$59K	76,140	Form 4
Mar 31, 2026	Congleton Jon CEO · Director	Sale	19,364	$25.50	$494K	760,687	Form 4
Mar 31, 2026	Congleton Jon CEO · Director	Sale	55,183	$26.54	$1.46M⚡	705,504	Form 4
Mar 31, 2026	Congleton Jon CEO · Director	Sale	453	$27.05	$12K	705,051	Form 4
Mar 31, 2026	Karydas Daphne Director	Option	3,000	$12.02	$36K	9,200	Form 4
Mar 31, 2026	Karydas Daphne Director	Sale	3,000	$25.00	$75K	6,200	Form 4
Mar 30, 2026	RA CAPITAL MANAGEMENT, L.P. Director	Purchase	58,300	$24.16	$1.41M⚡	5,825,521	Form 4

Rodman David Malcom

Chief Medical Officer

Option

Date

May 18

417

Price

$15.44

Value

$6K

View Form 4 on SEC.gov

Rodman David Malcom

Chief Medical Officer

Sale

Date

May 18

417

Price

$27.55

Value

$11K

View Form 4 on SEC.gov

Rodman David Malcom

Chief Medical Officer

Option

Date

May 13

4,166

Price

$14.25

Value

$59K

View Form 4 on SEC.gov

Rodman David Malcom

Chief Medical Officer

Option

Date

May 12

6,348

Price

$1.08

Value

$7K

View Form 4 on SEC.gov

Rodman David Malcom

Chief Medical Officer

Option

Date

May 13

3,541

Price

$10.20

Value

$36K

View Form 4 on SEC.gov

Rodman David Malcom

Chief Medical Officer

Option

Date

May 11

2,171

Price

$16.00

Value

$35K

View Form 4 on SEC.gov

Rodman David Malcom

Chief Medical Officer

Sale

Date

May 12

6,348

Price

$29.36

Value

$186K

View Form 4 on SEC.gov

Rodman David Malcom

Chief Medical Officer

Sale

Date

May 11

2,171

Price

$29.71

Value

$65K

View Form 4 on SEC.gov

Rodman David Malcom

Chief Medical Officer

Sale

Date

May 13

14,056

Price

$28.58

Value

$402K

View Form 4 on SEC.gov

Rodman David Malcom

Chief Medical Officer

Option

Date

Apr 17

416

Price

$15.44

Value

$6K

View Form 4 on SEC.gov

Rodman David Malcom

Chief Medical Officer

Sale

Date

Apr 17

416

Price

$31.33

Value

$13K

View Form 4 on SEC.gov

Rodman David Malcom

Chief Medical Officer

Option

Date

Apr 13

4,167

Price

$14.25

Value

$59K

View Form 4 on SEC.gov

Rodman David Malcom

Chief Medical Officer

Option

Date

Apr 13

3,542

Price

$10.20

Value

$36K

View Form 4 on SEC.gov

Rodman David Malcom

Chief Medical Officer

Option

Date

Apr 13

6,349

Price

$1.08

Value

$7K

View Form 4 on SEC.gov

Rodman David Malcom

Chief Medical Officer

Sale

Date

Apr 13

14,058

Price

$26.54

Value

$373K

View Form 4 on SEC.gov

Rodman David Malcom

Chief Medical Officer

Sale

Date

Apr 15

6,348

Price

$27.66

Value

$176K

View Form 4 on SEC.gov

Congleton Jon

CEO · Director

Sale

Date

Apr 13

15,730

Price

$26.83

Value

$422K

View Form 4 on SEC.gov

Rodman David Malcom

Chief Medical Officer

Option

Date

Apr 9

2,170

Price

$16.00

Value

$35K

View Form 4 on SEC.gov

Rodman David Malcom

Chief Medical Officer

Sale

Date

Apr 9

2,170

Price

$27.38

Value

$59K

View Form 4 on SEC.gov

Congleton Jon

CEO · Director

Sale

Date

Mar 31

19,364

Price

$25.50

Value

$494K

View Form 4 on SEC.gov

Congleton Jon

CEO · Director

Sale

Date

Mar 31

55,183

Price

$26.54

Value

$1.46M ⚡

View Form 4 on SEC.gov

Congleton Jon

CEO · Director

Sale

Date

Mar 31

453

Price

$27.05

Value

$12K

View Form 4 on SEC.gov

Karydas Daphne

Director

Option

Date

Mar 31

3,000

Price

$12.02

Value

$36K

View Form 4 on SEC.gov

Karydas Daphne

Director

Sale

Date

Mar 31

3,000

Price

$25.00

Value

$75K

View Form 4 on SEC.gov

RA CAPITAL MANAGEMENT, L.P.

Director

Purchase

Date

Mar 30

58,300

Price

$24.16

Value

$1.41M ⚡

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 3

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About MLYS insider trading

MLYS insider trades

Mineralys Therapeutics, Inc. (MLYS) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Rodman David Malcom (Chief Medical Officer), Congleton Jon (CEO · Director), Karydas Daphne (Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. MLYS insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Mineralys Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

MLYS insider trading · 5 questions

The insiders of Mineralys Therapeutics, Inc. (MLYS) include executives and directors such as Rodman David Malcom (Chief Medical Officer), Congleton Jon (CEO · Director), Karydas Daphne (Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

MLYS board member insider tradingwho are MLYS insidersMLYS insider rosterMineralys Therapeutics, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026